ORTX News and Press, Orchard Therapeutics plc From 03/03/23

BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences: TD Cowen 43 rd Annual Healthcare Conference on March 7, 2023...

BOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all m...

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite primary endpoint used in analysis was developed through ongoing discussions with the U.S. Foo...

Orchard Therapeutics ( NASDAQ: ORTX ) said it plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value £0.10 per share, to a new ADS Ratio of one ADS to ten ordinary shares. The company expects the ADS ratio change to be effective on or ab...

BOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value £0.10 per share, from t...

BOSTON and LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a series of presentations from across its neurometabolic portfolio will be featured at the 19th Annual WORLD Symposium taking place February 22-26, 2023, in ...

Libmeldy ® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200 (MLD) BLA submission Ended 2022 with approximately $144M...

Red Hot Penny Stocks Moving Higher After Headlines One of the go-to strategies for finding penny stocks to buy – at least for some traders – is identifying obvious catalysts. One of the most “obvious” typically comes in the form of company news. It takes more dilig...

Orchard Therapeutics ( NASDAQ: ORTX ) announced Thursday that the FDA cleared its Investigational New Drug (IND) application for OTL-203, targeted at the neurometabolic disease, Hurler subtype of mucopolysaccharidosis type I (MPS-IH). Orchard ( ORTX ), a biotech focused on gene th...

BOSTON and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OTL-203, a hematopoietic stem cell (HSC) gene therapy ...